image
Healthcare - Biotechnology - NASDAQ - IL
$ 3.75
-4.74 %
$ 38.2 M
Market Cap
-0.85
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one PYPD stock under the worst case scenario is HIDDEN Compared to the current market price of 3.75 USD, PolyPid Ltd. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one PYPD stock under the base case scenario is HIDDEN Compared to the current market price of 3.75 USD, PolyPid Ltd. is HIDDEN

This DCF valuation model was last updated on Jul, 21, 2025.

The intrinsic value of one PYPD stock under the best case scenario is HIDDEN Compared to the current market price of 3.75 USD, PolyPid Ltd. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PYPD

image
$3.8$3.8$3.6$3.6$3.4$3.4$3.2$3.2$3.0$3.0$2.8$2.8$2.6$2.6$2.4$2.4$2.2$2.2Feb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 Jul
FINANCIALS
0 REVENUE
0.00%
-28 M OPERATING INCOME
-22.57%
-29 M NET INCOME
-21.61%
-22 M OPERATING CASH FLOW
-27.43%
-330 K INVESTING CASH FLOW
-8.68%
32.4 M FINANCING CASH FLOW
224.94%
0 REVENUE
0.00%
-7.58 M OPERATING INCOME
7.81%
-6.36 M NET INCOME
-13.42%
0 OPERATING CASH FLOW
0.00%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet PolyPid Ltd.
image
Current Assets 16.6 M
Cash & Short-Term Investments 15.6 M
Receivables 0
Other Current Assets 932 K
Non-Current Assets 8.65 M
Long-Term Investments 0
PP&E 8.37 M
Other Non-Current Assets 277 K
62.02 %3.70 %33.19 %Total Assets$25.2m
Current Liabilities 12.7 M
Accounts Payable 2.41 M
Short-Term Debt 7.71 M
Other Current Liabilities 2.57 M
Non-Current Liabilities 4.86 M
Long-Term Debt 1.91 M
Other Non-Current Liabilities 2.94 M
13.74 %43.94 %14.63 %10.90 %16.79 %Total Liabilities$17.5m
EFFICIENCY
Earnings Waterfall PolyPid Ltd.
image
Revenue 0
Cost Of Revenue 1.62 M
Gross Profit -1.62 M
Operating Expenses 26.4 M
Operating Income -28 M
Other Expenses 993 K
Net Income -29 M
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)0(2m)(2m)(26m)(28m)(993k)(29m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-377.69% ROE
-377.69%
-115.08% ROA
-115.08%
-138.65% ROIC
-138.65%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis PolyPid Ltd.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -29 M
Depreciation & Amortization 1.62 M
Capital Expenditures -76 K
Stock-Based Compensation 2.82 M
Change in Working Capital 1.92 M
Others 976 K
Free Cash Flow -22 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets PolyPid Ltd.
image
Wall Street analysts predict an average 1-year price target for PYPD of $9.5 , with forecasts ranging from a low of $9 to a high of $10 .
PYPD Lowest Price Target Wall Street Target
9 USD 140.00%
PYPD Average Price Target Wall Street Target
9.5 USD 153.33%
PYPD Highest Price Target Wall Street Target
10 USD 166.67%
Price
Max Price Target
Min Price Target
Average Price Target
10109988776655443322Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 4
6. Ownership
Insider Ownership PolyPid Ltd.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of weekly injections. The GLP-1 delivery platform expands PolyPid's product portfolio beyond the recently successful Phase 3 D-PLEX100, demonstrating versatility of the Company's proprietary drug delivery platforms in multiple major therapeutic areas. globenewswire.com - 1 week ago
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that following its recently announced successful SHIELD II phase 3 topline results, it has secured additional funding through the exercise of warrants with aggregate gross proceeds of $26.7 million. The Company anticipates that with this additional funding, PolyPid's runway would be extended beyond anticipated FDA approval of D-PLEX₁₀₀. globenewswire.com - 1 month ago
PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future globenewswire.com - 1 month ago
PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future PESG issues a new briefing following PolyPid's clinical success; Revolutionary 58% Reduction in Surgical Site Infections Positions PolyPid's D-PLEX100 as Potential New Standard of Care in the Future globenewswire.com - 1 month ago
BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal colorectal surgery patients with large incisions. globenewswire.com - 1 month ago
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints PETACH TIKVA, Israel, June 09, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced positive topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 for the prevention of SSIs in patients undergoing abdominal colorectal surgery with large incisions, which has received Fast Track designation from the FDA. globenewswire.com - 1 month ago
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025 PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. globenewswire.com - 1 month ago
PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology New report from PESG Research brand covers PolyPid*, which is tackleing the $10 billion dollar a year surgeical site infections cost with its innovative PLEX technology globenewswire.com - 1 month ago
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025 PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025. globenewswire.com - 2 months ago
PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript PolyPid Ltd. (NASDAQ:PYPD ) Q1 2025 Earnings Call May 14, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations Dikla Czaczkes Akselbrad - Chief Executive Officer Jonny Missulawin - Chief Financial Officer Ori Warshavsky - Chief Operating Officer, U.S. Conference Call Participants Roy Buchanan - JMP Securities Chase Knickerbocker - Craig-Hallum Bupalan Pachaiyappan - ROTH Capital Brian Ritchie Thank you all for participating in PolyPid's First Quarter 2025 Earnings Conference Call. seekingalpha.com - 2 months ago
PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results PolyPid Successfully Completed Enrollment in Phase 3 SHIELD II Trial of D-PLEX100 , with Top-Line Results Anticipated in Current Quarter Company Continues to Advance Regulatory Submission Preparations, Commercial Launch Preparations and Partnering Discussions Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 14, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three months ended March 31, 2025. globenewswire.com - 2 months ago
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025 PETACH TIKVA, Israel, April 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 14, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. globenewswire.com - 2 months ago
8. Profile Summary

PolyPid Ltd. PYPD

image
COUNTRY IL
INDUSTRY Biotechnology
MARKET CAP $ 38.2 M
Dividend Yield 0.00%
Description PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
Contact 18 Hasivim Street, Petah Tikva, 4959376 https://www.polypid.com
IPO Date June 26, 2020
Employees 57
Officers Ms. Dikla Czaczkes Akselbrad Chief Executive Officer & Director Ms. Dalit Hazan Deputy Chief Executive Officer and Executive Vice President of R&D, Clinical & Regulatory Affairs Ms. Rivi Lev-ari Vice President of Human Resource Mr. Jonny Missulawin Chief Financial Officer Ms. Maria Rubin Executive Vice President of Operations Mr. Tal Vilnai General Counsel & Corporate Secretary Dr. Jean-Marc Hagai Pharm.D. Chief Commercial Officer Mr. Ori Warshavsky Chief Operating Officer - US